Dear HD Community,
The Associação Brasil Huntington, in collaboration with BioDecision Analytics, invites you to a webinar on 🗓️ July 18th at 12pm BRT (UTC -3) to better understand the potential of pharma intelligence to transform Huntington’s disease treatment.
In this webinar, Dr. Rodrigo P. Araldi will explore the concept of pharma intelligence and how BioDecision’s innovative methodology, combining RNA sequencing and Artificial Intelligence (AI), is identifying new molecular targets for Huntington’s disease treatment.
💻 Webinar: Pharma Intelligence and Huntington’s Disease: Unveiling New Treatment Horizons
🗓️ Date: July 18th, 2024
⏰ HD Community: 12:00 PM – 1:15 PM BRT (UTC -3)
⏰ Professionals, Researchers and Pharmaceutical Industry: 1:15 PM – 2:30 PM BRT (UTC -3)
REGISTER NOW ➡️ https://bit.ly/BioDecisionWebinar
HD Community Webinar starts at 12:00 PM BRT / 11:00 PM EDT / 3:00 PM GMT / 4:00 PM WEST / 5:00 PM CEST
Professionals, Researchers and Pharmaceutical Industry Webinar starts at 1:15 PM BRT / 12:15 PM EDT / 4:15 PM GMT / 5:15 PM WEST / 6:15 PM CEST
Key Topics:
- Introduction to pharma intelligence and its role in drug development
- Overview of BioDecision’s BDASeq methodology and its application in Huntington’s disease research
- Discussion of the newly identified therapeutic targets and their potential impact on treatment
- Q&A session
This webinar is open to members of the HD community, researchers, healthcare professionals, and industry representatives interested in the latest advancements in Huntington’s disease research.
Please fill out the registration form to receive a Zoom link to attend the webinar.
For any questions, please email us at: comunicacao.abh@gmail.com
Kind regards,
Associação Brasil Huntington (ABH)
Summary from researchers
Huntington’s disease (HD) is a fatal neurodegenerative disorder. Although the genetic basis of the disease has been known for more than three decades, the lack of therapeutic targets, added to the absence of prognostic biomarkers, are recognized as the main factors responsible for the lack of approved treatments that can slow or even prevent the progression of the disease.
In this sense, multi-omics analyses, especially global gene expression analysis (transcriptomics/RNA sequencing) offer unique opportunities to identify possible therapeutic targets and/or prognostic biomarkers. However, despite the notorious efforts, the differentially expressed genes identified in the brain (post-mortem samples) or blood of individuals with HD revealed targets of little relevance for drug development or monitoring of the natural evolution of the disease.
Using an innovative technology (BDASeq), which employs bioinformatics, data analytics, artificial intelligence and statistics to intelligently combine transcriptomic data with clinical-pathological variables, BioDecision conducted the largest HD study ever done. This study, supported by the Brazil Huntington Association (ABH), the International Huntington Association (IHA), the Brazilian Alzheimer’s Federation (FeBraz) and the Sindusfarma, and financial supported by the São Paulo Research Foundation (FAPESP, PIPE Project) analyzed more than 2 Tb of transcriptomic data, collected from 292 individuals, available in international public repositories of genetic data. Using BDASeq, BioDecision has identified 394 potential therapeutic targets for HD that have never been identified before. In addition, among these 394 targets, BDASeq identified specific targets that, if pharmacologically modified, can delay the onset of disease and even increase the life expectancy of individuals with HD. In addition, the study identified, for the first time, a biomarker that, because it is differentially expressed in the brain and blood, and because it is related to the onset of the disease, can be used as a biomarker for clinical trials.
The BDASeq also identified that these targets can be pharmacologically modified by a set of already approved drugs, some of which have already been prescribed for the management of signs and symptoms of HD, but without a basis for a mechanism of action that would justify the prescription of these drugs. Thus, the results of the work conducted by BioDecision not only offer the possibility of designing new effective drugs, but also of repurposing already approved drugs or combinations of them for the treatment of HD.
We also clarify that both the BDASeq model, and the results obtained by it were awarded at the largest rare disease event in the world (MENA Congress for Rare Disease, Abu Dhabi, 16-19 May 2024). In addition, we emphasize that the targets identified for HD are also useful for the development of therapies that can prevent the natural aging of the brain, also offering therapeutic opportunities for diseases such as Parkinson’s, Alzheimer’s and even Friedrich’s ataxia.